LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice

Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice

(2019) Seun Deuk Hwang et al.   Cell Death & Disease

LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis

(2019) Qing Ge et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease

(2018) Yasunori Suematsu et al.   JOURNAL OF CARDIAC FAILURE

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats

(2018) Toru Miyoshi et al.   Cardiology Journal

LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy

(2017) Yan Xia et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial InfarctionCLINICAL PERSPECTIVE

(2016) Orianne Henri et al.   CIRCULATION

LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice

(2016) Yasunori Suematsu et al.   EUROPEAN JOURNAL OF HEART FAILURE

LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone

(2015) Hiroaki Kusaka et al.   AMERICAN JOURNAL OF HYPERTENSION

Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts

(2015) A. Dashkevich et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cardiac lymphatics are heterogeneous in origin and respond to injury

(2015) Linda Klotz et al.   NATURE

Cytokines are systemic effectors of lymphatic function in acute inflammation

(2013) Melissa B. Aldrich et al.   CYTOKINE

The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

(2013) Adriaan A Voors et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

Regulation and implications of inflammatory lymphangiogenesis

(2012) Honsoul Kim et al.   TRENDS IN IMMUNOLOGY

LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma

(2012) Pramila Ramani et al.   VIRCHOWS ARCHIV

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload

(2008) Ying Xia et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Lymphangiogenesis and lymph node metastasis in breast cancer

(2008) Giles H Cunnick et al.   Molecular Cancer